myasthenia gravis

Summary

Summary: A disorder of neuromuscular transmission characterized by weakness of cranial and skeletal muscles. Autoantibodies directed against acetylcholine receptors damage the motor endplate portion of the NEUROMUSCULAR JUNCTION, impairing the transmission of impulses to skeletal muscles. Clinical manifestations may include diplopia, ptosis, and weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles. THYMOMA is commonly associated with this condition. (Adams et al., Principles of Neurology, 6th ed, p1459)

Top Publications

  1. ncbi Thymoma in patients with MG: characteristics and long-term outcome
    A Evoli
    Institute of Neurology, Catholic University, L go F Vito, 1 00168 Rome, Italy
    Neurology 59:1844-50. 2002
  2. pmc Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity
    Matthew N Meriggioli
    Department of Neurology and Rehabilitation, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA
    Lancet Neurol 8:475-90. 2009
  3. ncbi Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis
    Bin Zhang
    Department of Neurology, Institute of Molecular Medicine and Genetics, Georgia Health Sciences University, 1120 15th St, Augusta, GA 30912, USA
    Arch Neurol 69:445-51. 2012
  4. pmc Myasthenia gravis: past, present, and future
    Bianca M Conti-Fine
    Department of Biochemistry, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Clin Invest 116:2843-54. 2006
  5. ncbi Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature
    S Jarius
    Division of Molecular Neuroimmunology, Department of Neurology, University of Heidelberg, Heidelberg, Germany
    Mult Scler 18:1135-43. 2012
  6. ncbi Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis
    Alexandra Pevzner
    Department of Physiological Genomics, Institute for Physiology, Ludwig Maximilians University, Pettenkoferstrasse 12, 80336, Munich, Germany
    J Neurol 259:427-35. 2012
  7. ncbi The search for new antigenic targets in myasthenia gravis
    Judith Cossins
    Nuffield Department of Clinical Neurosciences, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    Ann N Y Acad Sci 1275:123-8. 2012
  8. ncbi Autoimmune mechanisms in myasthenia gravis
    Paola Cavalcante
    Department of Neurology IV, Neuromuscular Diseases and Neuroimmunology, Fondazione Istituto Neurologico Carlo Besta, Milan, Italy
    Curr Opin Neurol 25:621-9. 2012
  9. pmc Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08
    Peter K Gregersen
    Robert S Boas Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, North Shore LIJ Health System, Manhasset, NY 11030, USA
    Ann Neurol 72:927-35. 2012
  10. ncbi The autoimmunity-related polymorphism PTPN22 1858C/T is associated with anti-titin antibody-positive myasthenia gravis
    Bernhard Greve
    Department of General Neurology, Hertie Institute for Clinical Brain Research, Tubingen, Germany
    Hum Immunol 70:540-2. 2009

Detail Information

Publications352 found, 100 shown here

  1. ncbi Thymoma in patients with MG: characteristics and long-term outcome
    A Evoli
    Institute of Neurology, Catholic University, L go F Vito, 1 00168 Rome, Italy
    Neurology 59:1844-50. 2002
    ..To examine the characteristics of thymoma when associated with MG and to evaluate those conditions that can complicate management and affect survival...
  2. pmc Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity
    Matthew N Meriggioli
    Department of Neurology and Rehabilitation, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA
    Lancet Neurol 8:475-90. 2009
    Acquired myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction in which patients experience fluctuating skeletal muscle weakness that often affects selected muscle groups preferentially...
  3. ncbi Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis
    Bin Zhang
    Department of Neurology, Institute of Molecular Medicine and Genetics, Georgia Health Sciences University, 1120 15th St, Augusta, GA 30912, USA
    Arch Neurol 69:445-51. 2012
    To determine whether patients with myasthenia gravis (MG) have serum antibodies to lipoprotein-related protein 4 (LRP4), a newly identified receptor for agrin that is essential for neuromuscular junction formation, and to establish ..
  4. pmc Myasthenia gravis: past, present, and future
    Bianca M Conti-Fine
    Department of Biochemistry, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Clin Invest 116:2843-54. 2006
    b>Myasthenia gravis (MG) is an autoimmune syndrome caused by the failure of neuromuscular transmission, which results from the binding of autoantibodies to proteins involved in signaling at the neuromuscular junction (NMJ)...
  5. ncbi Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature
    S Jarius
    Division of Molecular Neuroimmunology, Department of Neurology, University of Heidelberg, Heidelberg, Germany
    Mult Scler 18:1135-43. 2012
    Neuromyelitis optica (NMO, Devic syndrome) and myasthenia gravis (MG) are rare antibody-mediated autoimmune disorders. Concurrent incidence has been reported in only few patients, mostly non-Caucasians.
  6. ncbi Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis
    Alexandra Pevzner
    Department of Physiological Genomics, Institute for Physiology, Ludwig Maximilians University, Pettenkoferstrasse 12, 80336, Munich, Germany
    J Neurol 259:427-35. 2012
    b>Myasthenia gravis (MG) is an autoimmune disorder characterized by a defect in synaptic transmission at the neuromuscular junction causing fluctuating muscle weakness with a decremental response to repetitive nerve stimulation or altered ..
  7. ncbi The search for new antigenic targets in myasthenia gravis
    Judith Cossins
    Nuffield Department of Clinical Neurosciences, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    Ann N Y Acad Sci 1275:123-8. 2012
    Around 80% of myasthenia gravis patients have antibodies against the acetylcholine receptor, and 0-60% of the remaining patients have antibodies against the muscle-specific tyrosine kinase, MuSK...
  8. ncbi Autoimmune mechanisms in myasthenia gravis
    Paola Cavalcante
    Department of Neurology IV, Neuromuscular Diseases and Neuroimmunology, Fondazione Istituto Neurologico Carlo Besta, Milan, Italy
    Curr Opin Neurol 25:621-9. 2012
    This article reviews recent findings on factors and mechanisms implicated in the pathogenesis of myasthenia gravis and briefly summarizes data on therapies acting at various stages of the autoimmune process.
  9. pmc Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08
    Peter K Gregersen
    Robert S Boas Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, North Shore LIJ Health System, Manhasset, NY 11030, USA
    Ann Neurol 72:927-35. 2012
    The objective of this study is to comprehensively define the genetic basis of early onset myasthenia gravis (EOMG).
  10. ncbi The autoimmunity-related polymorphism PTPN22 1858C/T is associated with anti-titin antibody-positive myasthenia gravis
    Bernhard Greve
    Department of General Neurology, Hertie Institute for Clinical Brain Research, Tubingen, Germany
    Hum Immunol 70:540-2. 2009
    ..b>Myasthenia gravis (MG) is a complex genetic disease with a distinct clinical and pathological heterogeneity...
  11. pmc Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia
    Claire Vandiedonck
    Institut National de la Santé et de la Recherche Médicale U580 and Institut de Recherche Necker Enfants Malades, 161 rue de Sevres, 75743 Paris Cedex 15, France
    Proc Natl Acad Sci U S A 101:15464-9. 2004
    ..autoimmune diseases and traits, notably with thymus hyperplasia in patients with acquired generalized myasthenia gravis, an autoantibody-mediated disease directed at the muscle acetylcholine receptor...
  12. ncbi Increased Bax/Bcl-2 ratio up-regulates caspase-3 and increases apoptosis in the thymus of patients with myasthenia gravis
    Stavroula Salakou
    Department of Neurology, University of Patras, School of Medicine, Patras, Greece
    In Vivo 21:123-32. 2007
    ..an apoptosis promoter) to Bcl-2 (an apoptosis inhibitor) ratio with the apoptosis co-ordination enzyme, caspase-3, in the thymus of patients with myasthenia gravis (MG) was investigated in correlation with long-term clinical prognosis.
  13. ncbi IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial
    Lorne Zinman
    Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    Neurology 68:837-41. 2007
    We aimed to determine the effectiveness of IV immunoglobulin (IVIG) in the treatment of patients with myasthenia gravis (MG) and worsening weakness in a randomized, placebo-controlled, masked study.
  14. ncbi An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis
    D B Sanders
    Division of Neurology, Duke University Medical Center, Durham, NC, USA
    Neurology 71:400-6. 2008
    This prospective, randomized, double-blind, placebo-controlled, phase III trial assessed the efficacy, safety, and tolerability of mycophenolate mofetil (MMF) as a steroid-sparing agent in patients with myasthenia gravis (MG).
  15. ncbi Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase
    Z Argov
    Department of Neurology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Neurology 69:699-700. 2007
  16. ncbi Tacrolimus for myasthenia gravis: a clinical study of 212 patients
    José M Ponseti
    Unit of Myasthenia Gravis, Department of Surgery, Hospital General Universitari Vall d Hebron, Passeig Vall d Hebron 119 129, E 08035 Barcelona, Spain
    Ann N Y Acad Sci 1132:254-63. 2008
    Tacrolimus is a macrolide T cell immunomodulator that is used in myasthenia gravis (MG) patients to affect muscle contraction (ryanodine receptor by modulating intracellular calcium-release channels and increasing muscular strength), ..
  17. ncbi Clinical study of FK506 in patients with myasthenia gravis
    Tetsuro Konishi
    Department of Neurology, Utano National Hospital, 8 Ondoyama cho, Narutaki, Kyoto 616 8255, Japan
    Muscle Nerve 28:570-4. 2003
    To investigate the usefulness of low-dose FK506 for the treatment of myasthenia gravis (MG), we treated 19 patients with generalized MG in a 16-week open clinical trial of FK506 (3-5 mg/day)...
  18. ncbi Immunosuppressive therapies in myasthenia gravis
    Donald B Sanders
    Duke University Medical Center, Durham, NC 27705, USA
    Autoimmunity 43:428-35. 2010
    Immunosuppression is the mainstay of treatment for myasthenia gravis (MG)...
  19. pmc IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis
    Maria Isabel Leite
    Neurosciences Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK
    Brain 131:1940-52. 2008
    Only around 80% of patients with generalized myasthenia gravis (MG) have serum antibodies to acetylcholine receptor [AChR; acetylcholine receptor antibody positive myasthenia gravis (AChR-MG)] by the radioimmunoprecipitation assay used ..
  20. ncbi Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus
    Paola Cavalcante
    Department of Neurology IV, Neuromuscular Diseases and Neuroimmunology, Fondazione Istituto Neurologico Carlo Besta, Milan, Italy
    Ann Neurol 67:726-38. 2010
    ..We sought evidence of EBV infection in thymuses from patients with myasthenia gravis (MG), an autoimmune disease characterized by intrathymic B-cell activation.
  21. ncbi Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies
    W Hoch
    Max Planck Institute for Developmental Biology, , Germany
    Nat Med 7:365-8. 2001
    b>Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction. In approximately 80% of patients, auto-antibodies to the muscle nicotinic acetylcholine receptor (AChR) are present...
  22. ncbi Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis
    Claire Vandiedonck
    Institut National de la Sante et de la Recherche Medicale, Universite Paris Descartes, France
    Ann Neurol 59:404-7. 2006
    Our objective was to investigate a role of the intracellular tyrosine phosphatase PTPN22*R620W variant in autoimmune myasthenia gravis (MG), considering disease heterogeneity.
  23. pmc MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4
    Maartje G Huijbers
    Department of Neurology, Department of Human Genetics and Department of Molecular Cell Biology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands
    Proc Natl Acad Sci U S A 110:20783-8. 2013
    b>Myasthenia gravis (MG) is a severely debilitating autoimmune disease that is due to a decrease in the efficiency of synaptic transmission at neuromuscular synapses...
  24. ncbi The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis
    W Y Chuang
    Institute of Pathology, University of Wurzburg, Wurzburg, Germany
    Genes Immun 10:667-72. 2009
    ..genotypes predispose to multiple autoimmune diseases, including early-onset (non-thymomatous) myasthenia gravis (MG)...
  25. ncbi CDS1 and promoter single nucleotide polymorphisms of the CTLA-4 gene in human myasthenia gravis
    X B Wang
    Immunological Research Unit, Center for Molecular Medicine and Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    Genes Immun 3:46-9. 2002
    ..There was a strong linkage between the 86bp allele in the 3'-UTR and the A(+49) allele in CDS1. Our results suggest that the SNP at position +49 in CDS1 might be associated with the manifestations of MG...
  26. ncbi Tetanic failure due to decreased endogenous adenosine A(2A) tonus operating neuronal Ca(v) 1 (L-type) influx in Myasthenia gravis
    J B Noronha-Matos
    Laboratório de Farmacologia e Neurobiologia UMIB, Instituto de Ciencias Biomedicas de Abel Salazar, Universidade do Porto, L Prof Abel Salazar 2, Porto, Portugal
    J Neurochem 117:797-811. 2011
    ..1 (L)-type channels contribute to sustain acetylcholine release evoked by 50 Hz-bursts in toxin-induced Myasthenia gravis (TIMG) rats. In contrast to control animals, inhibition of [(3) H]acetylcholine (ACh) release by the Ca(V) 2...
  27. ncbi PTPN22 R620W promotes production of anti-AChR autoantibodies and IL-2 in myasthenia gravis
    Ann Kari Lefvert
    Immunological Research Unit, Centre for Molecular Medicine, Karolinska University Hospital Solna, SE 17176 Stockholm, Sweden
    J Neuroimmunol 197:110-3. 2008
    In order to investigate the potential involvement of PTPN22 R620W in the pathogenesis of myasthenia gravis (MG), we performed a case-control study including 409 Swedish MG patients and 1557 normal controls...
  28. ncbi Clonal expansions of CD4+ B helper T cells in autoimmune myasthenia gravis
    Björn Tackenberg
    Clinical Neuroimmunology Group, Department of Neurology, Philipps University, Marburg, Germany
    Eur J Immunol 37:849-63. 2007
    The weakness in myasthenia gravis (MG) is mediated by T helper cell (Th)-dependent autoantibodies against neuromuscular epitopes. So far, analyzing Th phenotypes or antigen specificities has yielded very few clues to pathogenesis...
  29. ncbi Altered let-7 expression in Myasthenia gravis and let-7c mediated regulation of IL-10 by directly targeting IL-10 in Jurkat cells
    Lin Jiang
    State Key Laboratory of Bioreactor Engineering and Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, PR China
    Int Immunopharmacol 14:217-23. 2012
    b>Myasthenia gravis (MG) is a T cell-dependent and B cell-mediated autoimmune disease of neuromuscular junctions and cytokines may play a crucial role in the pathogenesis and perpetuation of MG...
  30. ncbi Animal models of myasthenia gravis
    P Christadoss
    Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas 77555 1070, USA
    Clin Immunol 94:75-87. 2000
    b>Myasthenia gravis (MG) is an antibody-mediated, autoimmune neuromuscular disease...
  31. pmc Muscle autoantibodies in myasthenia gravis: beyond diagnosis?
    Matthew N Meriggioli
    Department of Neurology and Rehabilitation, College of Medicine, University of Illinois Hospital and Health Sciences System, Chicago, IL 60612, USA
    Expert Rev Clin Immunol 8:427-38. 2012
    b>Myasthenia gravis is an autoimmune disorder of the neuromuscular junction...
  32. ncbi The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes
    Alexander Marx
    Institute of Pathology, University Medical Centre Mannheim, University of Heidelberg, Theodor Kutzer Ufer 1 3, D 68167 Mannheim, Germany
    Autoimmun Rev 12:875-84. 2013
    The thymus plays distinct roles in the pathogenesis of the different Myasthenia gravis (MG) subtypes...
  33. pmc The features of myasthenia gravis with autoantibodies to MuSK
    D Lavrnic
    The Institute of Neurology, Clinical Centre of Serbia, 11000 Belgrade, 6 Dr Subotica Street, Serbia and Montenegro
    J Neurol Neurosurg Psychiatry 76:1099-102. 2005
    To determine if myasthenia gravis (MG) with antibodies to MuSK is a distinct subgroup of seronegative MG.
  34. ncbi Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction
    Alejandro M Gomez
    Neuroimmunology Group, Department of Neuroscience, School of Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands
    Autoimmunity 43:353-70. 2010
    b>Myasthenia gravis (MG) is an autoimmune disorder caused by autoantibodies that are either directed to the muscle nicotinic acetylcholine receptor (AChR) or to the muscle-specific tyrosine kinase (MuSK)...
  35. ncbi Efficacy of low-dose FK506 in the treatment of Myasthenia gravis--a randomized pilot study
    Yuriko Nagane
    Department of Neurology, Iwate Medical University, Morioka, Japan
    Eur Neurol 53:146-50. 2005
    To determine the efficacy of low-dose FK506 in the treatment of myasthenia gravis (MG), untreated de novo patients were randomly selected to receive treatment with (n = 18) or without (n = 16) FK506, and were evaluated for 1 year after ..
  36. ncbi Cyclosporine in the treatment of myasthenia gravis
    D Lavrnic
    Institute of Neurology, Clinical Center of Serbia, Belgrade, Serbia and Montenegro
    Acta Neurol Scand 111:247-52. 2005
    Cyclosporine A (CsA) treatment was evaluated in 52 patients with severe generalized myasthenia gravis (MG) whose illness was not controlled by anticholinesterase drugs, thymectomy, corticosteroids, and azathioprine...
  37. ncbi Thymectomy for myasthenia gravis: a 27-year experience
    F Venuta
    Department of Thoracic Surgery, University of Rome La Sapienza, Italy
    Eur J Cardiothorac Surg 15:621-4; discussion 624-5. 1999
    Thymectomy is considered an effective therapeutic option for patients with myasthenia gravis (MG). We reviewed our 27-year experience with surgical treatment of MG with respect to long-term results and factors affecting outcome.
  38. ncbi Antisense treatment for myasthenia gravis: experience with monarsen
    Jon D Sussman
    Department of Neurology, Greater Manchester Neuroscience Centre, Hope Hospital, Stott Lane, Salford, Greater Manchester UK M6 8HD
    Ann N Y Acad Sci 1132:283-90. 2008
    Acetylcholinesterase pre-mRNA is susceptible to alternative splicing. Myasthenia gravis has been shown to be associated with the expression of the readthrough transcript (AChE-R), which, unlike the normal "synaptic" transcript (AChE-S) ..
  39. ncbi Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis
    J Rønager
    Department of Neurology, Neuroscience Center, National University Hospital, Copenhagen, Denmark
    Artif Organs 25:967-73. 2001
    ..immunoglobulin (IVIG) treatment with plasma exchange in patients suffering from moderate to severe myasthenia gravis (MG) in a stable phase...
  40. ncbi Steroids and immunosuppressant drugs in myasthenia gravis
    Sivakumar Sathasivam
    Walton Centre for Neurology and Neurosurgery, Liverpool, UK
    Nat Clin Pract Neurol 4:317-27. 2008
    In chronic autoimmune conditions such as myasthenia gravis (MG), immunosuppression--usually long-term--is often necessary...
  41. ncbi Treatment of autoimmune myasthenia gravis
    David P Richman
    University of California, Davis 95616, USA
    Neurology 61:1652-61. 2003
    Autoimmune myasthenia gravis (MG) is associated with antibodies directed against the nicotinic acetylcholine receptor (AChR) in 85% of patients. Other postsynaptic neuromuscular junction antigens are implicated, e.g...
  42. ncbi Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis
    Osamu Higuchi
    Division of Genetics, Department of Cancer Biology, The Institute of Medical Science, The University of Tokyo, Japan
    Ann Neurol 69:418-22. 2011
    b>Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction, where acetylcholine receptor (AChR), muscle-specific kinase (MuSK), and low-density lipoprotein (LDL) receptor-related protein 4 (Lrp4) are essential...
  43. ncbi Genetic factors in autoimmune myasthenia gravis
    Matthieu Giraud
    Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA
    Ann N Y Acad Sci 1132:180-92. 2008
    Autoimmune myasthenia gravis (MG) is a multifactorial disease, markedly influenced by genetic factors, even though it shows limited heritability...
  44. ncbi Clinical evaluation and management of myasthenia gravis
    John C Keesey
    Department of Neurology, UCLA School of Medicine, Los Angeles, California, USA
    Muscle Nerve 29:484-505. 2004
    b>Myasthenia gravis (MG) is a syndrome of fluctuating skeletal muscle weakness that worsens with use and improves with rest...
  45. ncbi Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial
    Philippe Gajdos
    Medical Intensive Care Unit, Raymond Poincaré Teaching Hospital, Assistance Publique Hopitaux de Paris, Garches, France
    Arch Neurol 62:1689-93. 2005
    The optimal dose of intravenous immunoglobulin (IVIG) in acute exacerbation of myasthenia gravis remains unknown. Increasing the treatment duration might provide added efficacy.
  46. ncbi Clinical aspects of MuSK antibody positive seronegative MG
    D B Sanders
    Division of Neurology, Duke University Medical Center, Durham, NC 27710, USA
    Neurology 60:1978-80. 2003
    ..All patients improved after plasma exchange, and most had a good response to selected immunotherapy. MuSK antibody status should help diagnose MG with atypical presentations and ensure appropriate patient treatment...
  47. ncbi Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production
    Caishu Deng
    Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555 1070, USA
    J Immunol 169:1077-83. 2002
    To provide direct genetic evidence for a role of IL-6 in experimental autoimmune myasthenia gravis (EAMG), IL-6 gene KO (IL-6(-/-)) mice in the C57BL/6 background were immunized with Torpedo californica acetylcholine receptor (AChR) and ..
  48. ncbi Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis
    Hirokazu Shiraishi
    The First Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki, Japan
    Ann Neurol 57:289-93. 2005
    Muscle-specific tyrosine kinase (MuSK) antibodies are found in some patients with "seronegative" myasthenia gravis (MG), but how they cause myasthenic symptoms is not clear...
  49. ncbi Myasthenia gravis and the neuromuscular junction
    Luis Querol
    Neuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Curr Opin Neurol 26:459-65. 2013
    ..Their pathogenesis is diverse, including genetic and autoimmune mechanisms. We review recent findings on risk factors, pathogenesis and treatment of autoimmune myasthenia gravis.
  50. ncbi Association of thymoma and myasthenia gravis: oncological and neurological results of the surgical treatment
    Marco Lucchi
    Cardiac and Thoracic Department, Division of Thoracic Surgery, University of Pisa, Pisa, Italy
    Eur J Cardiothorac Surg 35:812-6; discussion 816. 2009
    Thymoma occurs in about 10-20% of myasthenic patients and in turn, 20-25% of patients with a thymoma have myasthenia gravis. Both diseases are treated by surgery...
  51. ncbi Response to therapy in myasthenia gravis with anti-MuSK antibodies
    Amelia Evoli
    Department of Neurosciences, Catholic University, Largo F Vito 1, 00168 Rome, Italy
    Ann N Y Acad Sci 1132:76-83. 2008
    b>Myasthenia gravis (MG) with antibodies against the muscle-specific tyrosine kinase (MuSK abs) is often a severe disease requiring aggressive treatment...
  52. ncbi HLA-DQA1*03:02/DQB1*03:03:02 is strongly associated with susceptibility to childhood-onset ocular myasthenia gravis in Southern Han Chinese
    Wen Hua Zhu
    Department of Neurology, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, China
    J Neuroimmunol 247:81-5. 2012
    Our aim was to investigate the correlation between onset age, clinical features and HLA-DQA1/DQB1 genetic variability in myasthenia gravis (MG) patients in Southern Han Chinese.
  53. ncbi Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG
    Maria Isabel Leite
    Neurosciences Group, Department of Clinical Neurology, University of Oxford, Oxford OX3 9DU, United Kingdom
    Ann Neurol 57:444-8. 2005
    In generalized myasthenia gravis (MG) patients without detectable acetylcholine receptor (AChR) antibodies (SNMG), the thymus is often reported as "normally involuted...
  54. ncbi Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis
    X B Wang
    Department of Respiratory Medicine, PuTuo Hospital, Shanghai University of TCM, Shanghai, China
    J Intern Med 263:61-9. 2008
    ..polymorphisms (SNPs) located in the promoter region are suspected to contribute to the pathogenesis of myasthenia gravis (MG) through regulation of gene expression...
  55. pmc Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001
    J F Owe
    Department of Clinical Medicine, Section for Neurology, University of Bergen, 5021 Bergen, Norway
    J Neurol Neurosurg Psychiatry 77:203-7. 2006
    This study investigated the causes of death among patients with myasthenia gravis (MG), with emphasis on respiratory tract and cardiac disease.
  56. ncbi Myasthenia gravis experimentally induced with muscle-specific kinase
    Kazuhiro Shigemoto
    Department of Preventive Medicine, Ehime University School of Medicine, Ehime, Japan
    Ann N Y Acad Sci 1132:93-8. 2008
    ..Notably, autoantibodies against MuSK were found in a proportion of patients with generalized myasthenia gravis (MG) but without the characteristic AChR autoantibodies...
  57. pmc Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status
    Maria I Leite
    Department of Clinical Neurology, University of Oxford, Oxford, United Kingdom
    Am J Pathol 171:893-905. 2007
    In early-onset myasthenia gravis, the thymus contains lymph node-type infiltrates with frequent acetylcholine receptor (AChR)-specific germinal centers...
  58. pmc Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis
    A Meager
    Division of Immunobiology, The National Institute for Biological Standards and Control, South Mimms, Herts, UK
    Clin Exp Immunol 132:128-36. 2003
    ..IgG, autoantibodies to IFN-alpha2, IFN-omega and IL-12 were common at diagnosis in patients with late-onset myasthenia gravis (LOMG+), thymoma (T) but no MG (TMG-) and especially with both thymoma and MG together (TMG+)...
  59. ncbi Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis
    Sandrine Poea-Guyon
    Unité Mixte de Recherche 8078, Centre National de la Recherche Scientifique Université Paris Sod, Institut Paris Sod Cytokines, Hopital Marie Lannelongue, Le Plessis Robinson, France
    J Immunol 174:5941-9. 2005
    b>Myasthenia gravis is an autoimmune disease associated with thymic pathologies, including hyperplasia...
  60. ncbi Lifetime course of myasthenia gravis
    David Grob
    Department of Medicine, Maimonides Medical Center, Brooklyn, New York 11219, USA
    Muscle Nerve 37:141-9. 2008
    Between 1940 and 2000 a total of 1976 patients with myasthenia gravis (MG) were studied. Diagnosis was made by improvement in weakness after anticholinesterase medication...
  61. ncbi Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite
    Ted M Burns
    University of Virginia, Department of Neurology, Charlottesville, Virginia 22908, USA
    Muscle Nerve 38:1553-62. 2008
    We assessed the performance of items from the Quantitative Myasthenia Gravis (QMG), MMT (Manual Muscle Test), and MG-ADL (Myasthenia Gravis - Activities of Daily Living) scales, using data from two recently completed treatment trials of ..
  62. ncbi A CTLA4high genotype is associated with myasthenia gravis in thymoma patients
    Wen Yu Chuang
    Institute of Pathology, University of Wurzburg, Wurzburg, Germany
    Ann Neurol 58:644-8. 2005
    b>Myasthenia gravis (MG) in thymoma patients depends critically on intratumorous generation and export of mature autoreactive CD4+ T cells. Why non-MG thymomas fail to produce CD4+ T cells is unknown...
  63. ncbi Thymoma, myasthenia gravis, and other paraneoplastic syndromes
    Laura M Tormoehlen
    Department of Neurology, Indiana University School of Medicine, Emerson Hall Room 125, 545 Barnhill Drive, Indianapolis, IN 46202, USA
    Hematol Oncol Clin North Am 22:509-26. 2008
    The relationship between myasthenia gravis and thymic pathology, including thymoma, is well known. Approximately 10% to 15% of patients who have myasthenia gravis are observed to have a thymoma...
  64. ncbi Altered expression of chemokine receptor CXCR5 on T cells of myasthenia gravis patients
    Ryuji Saito
    Department of Neurology, Tohoku University School of Medicine, 1 1 Seiryo machi, Aobaku, Sendai 980 8574, Japan
    J Neuroimmunol 170:172-8. 2005
    b>Myasthenia gravis (MG) is characterized by the T cell-dependent production of anti-acetylcholine receptor (AChR) antibodies...
  65. ncbi Thymectomy and antimuscle antibodies in nonthymomatous myasthenia gravis
    Fredrik Romi
    Department of Neurology, Haukeland University Hospital, N 5021 Bergen, Norway
    Ann N Y Acad Sci 998:481-90. 2003
    The clinical effect of thymectomy in early- and late-onset myasthenia gravis (MG) and the correlation to MG severity, pharmacological treatment, and antimuscle antibodies were examined in two series of consecutive acetylcholine receptor (..
  66. ncbi Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?
    Fulvio Baggi
    Preclinical Neuroimmunology Laboratory, Neurology IV Unit, Fondazione Istituto Neurologico Carlo Besta, Milan, Italy
    Arch Immunol Ther Exp (Warsz) 60:19-30. 2012
    b>Myasthenia gravis (MG) is an autoimmune disease caused by an immunological response against the acetylcholine receptor (AChR) at the neuromuscular junction...
  67. pmc Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients
    M I Leite
    Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, UK
    Neurology 78:1601-7. 2012
    To describe 16 patients with a coincidence of 2 rare diseases: aquaporin-4 antibody (AQP4-Ab)-mediated neuromyelitis optica spectrum disorder (AQP4-NMOSD) and acetylcholine receptor antibody (AChR-Ab)-mediated myasthenia gravis (AChR-MG).
  68. ncbi Recommendations for myasthenia gravis clinical trials
    Michael Benatar
    Department of Neurology, University of Miami School of Medicine, Miami, Florida, USA
    Muscle Nerve 45:909-17. 2012
    ..research standards published in 2000 by a task force of the Medical Scientific Advisory Board (MSAB) of the Myasthenia Gravis Foundation of America (MGFA) were largely successful in introducing greater uniformity in the recording and ..
  69. ncbi A novel galectin-1 and interleukin 2 receptor β haplotype is associated with autoimmune myasthenia gravis
    Zsuzsanna Pal
    Center for Molecular Neurology, Department of Neurology, Semmelweis University, Budapest, Hungary
    J Neuroimmunol 229:107-11. 2010
    ..polymorphisms of the LGALS1 (rs4820293, rs4820294) and IL2Rβ (rs743777, rs228941) genes in 146 Caucasian myasthenia gravis patients compared to 291 ethnically matched controls...
  70. pmc Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population
    Angelina H Maniaol
    Department of Neurology, Oslo University Hospital, Ulleval, Oslo, Norway
    PLoS ONE 7:e36603. 2012
    Acquired myasthenia gravis (MG) is a rare antibody-mediated autoimmune disease caused by impaired neuromuscular transmission, leading to abnormal muscle fatigability...
  71. ncbi Overlooked non-motor symptoms in myasthenia gravis
    Shigeaki Suzuki
    Department of Neurology, Keio University School of Medicine, Tokyo, Japan
    J Neurol Neurosurg Psychiatry 84:989-94. 2013
    Patients with myasthenia gravis (MG) may have various non-motor symptoms in addition to fatigability and weakness of skeletal muscles. Thymomas contain abundant immature thymocytes and developing CD4 and CD8 T cells...
  72. ncbi Expansion of circulating counterparts of follicular helper T cells in patients with myasthenia gravis
    Chuanming Luo
    Department of Neurology, The First Affiliated Hospital, Sun Yat Sen University, 58 Zhongshan 2nd Road, Guangzhou 510080, China
    J Neuroimmunol 256:55-61. 2013
    ..This study reveals that the frequency of circulating counterparts of TFH cells in myasthenia gravis (MG) patients is significantly higher compared to healthy controls...
  73. ncbi Frequency of autoimmune diseases in myasthenia gravis: a systematic review
    Zhi Feng Mao
    Department of Neurology, Third Affiliated Hospital, Guangxi Medical University, Nanning, PR China
    Int J Neurosci 121:121-9. 2011
    The course of myasthenia gravis (MG) may get complicated by the development of other autoimmune diseases...
  74. ncbi Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis
    Shuuichi Mori
    Department of Geriatric Medicine, Tokyo Metropolitan Institute of Gerontology, Tokyo 173 0015, Japan
    Autoimmun Rev 12:912-7. 2013
    ..of autoantibodies against muscle-specific kinase (MuSK) at the neuromuscular junction (NMJ) results in myasthenia gravis (MG)...
  75. ncbi Clinical aspects of myasthenia explained
    Jan J G M Verschuuren
    Department of Neurology, Leiden University Medical Center LUMC, Leiden, The Netherlands
    Autoimmunity 43:344-52. 2010
    b>Myasthenia gravis and myasthenic syndromes are diseases of the neuromuscular junction. Autoantibodies and toxins to or mutations in one of the synaptic proteins are the main causes of dysfunction...
  76. ncbi PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data
    Carlo Provenzano
    Institute of General Pathology, Catholic University, Largo Francesco Vito 1, 00168 Rome, Italy
    Neuromuscul Disord 22:131-8. 2012
    ..Results in myasthenia gravis are controversial...
  77. ncbi Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals
    A Alshekhlee
    Neurological Institute, University Hospitals Case Medical Center, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA
    Neurology 72:1548-54. 2009
    To determine the incidence and mortality rates and predictors of death in myasthenia gravis (MG) and MG crisis in a large US cohort.
  78. ncbi Myasthenia gravis: sleep quality, quality of life, and disease severity
    Elena Hernández Martínez-Lapiscina
    Department of Neurology, Complejo Hospitalario de Navarra, Irunlarrea Street, 3, 31008 Pamplona, Spain
    Muscle Nerve 46:174-80. 2012
    There is much research on quality of life in myasthenia gravis (MG), and its relationship to disease severity is well-established. However, evidence regarding sleep disturbance in MG is inconclusive.
  79. ncbi Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts
    Jeffrey T Guptill
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Muscle Nerve 44:36-40. 2011
    b>Myasthenia gravis (MG) patients with autoantibodies to muscle-specific tyrosine kinase (MuSK) represent a distinct subset of those with this disease. Treatment and outcomes data in these patients are limited and conflicting.
  80. ncbi Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis
    Jeffrey T Guptill
    Division of Neurology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Neurol 23:530-5. 2010
    ..clinical features, diagnosis and treatment of muscle-specific tyrosine kinase (MuSK) antibody positive myasthenia gravis will be reviewed...
  81. pmc Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice
    R N Cole
    Physiology, Anderson Stuart Bldg F13, University of Sydney, NSW 2006 Australia
    J Physiol 588:3217-29. 2010
    ..Daily injections of IgG from four MuSK autoantibody-positive myasthenia gravis patients (MuSK IgG; 45 mg day(1)i.p...
  82. ncbi Clinical outcome of video-assisted thymectomy for myasthenia gravis and thymoma
    Thirugnanam Agasthian
    National Cancer Center, 11 Hospital Drive, Singapore
    Asian Cardiovasc Thorac Ann 18:234-9. 2010
    We reviewed our experience of video-assisted thoracoscopic thymectomy for myasthenia gravis and thymomas in 119 patients, aged 12-83 years, who were treated between 1998 and 2007...
  83. ncbi Myasthenia gravis-associated neuromyelitis optica-like disease: an immunological link between the central nervous system and muscle?
    Adi Vaknin-Dembinsky
    Department of Neurology, Multiple Sclerosis Center and Immunobiology Research Laboratory, Hadassah University Hospital, Ein Kerem, PO Box 12000, Jerusalem 91120, Israel
    Arch Neurol 68:1557-61. 2011
    Although overt involvement of the central nervous system (CNS) in myasthenia gravis (MG) is considered rare, hyperreflexia is a common and yet unexplained finding...
  84. ncbi [Establishment and analysis of serum two-dimensional gel electrophoresis profiles of myasthenia gravis patients with spleen and kidney deficiency syndrome]
    Ping Liu
    Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
    Zhong Xi Yi Jie He Xue Bao 5:150-4. 2007
    The purpose of this study was to establish two-dimensional gel electrophoresis (2-DE) profiles of serum of myasthenia gravis patients, and to identify the differential proteomic expressions between normal persons and myasthenia gravis ..
  85. ncbi Seronegative myasthenia gravis
    Angela Vincent
    Department of Clinical Neurology, University of Oxford, Oxford, United Kingdom
    Semin Neurol 24:125-33. 2004
    Some myasthenia gravis (MG) patients do not have detectable acetylcholine receptor (AChR) antibodies and have been termed "seronegative" (SNMG) in many previous studies...
  86. ncbi Pathophysiology of myasthenia gravis
    Benjamin W Hughes
    Department of Neurology, Case Western Reserve University, Louis Stokes Cleveland DVA Medical Center, University Hospitals of Cleveland, Cleveland, Ohio 44106, USA
    Semin Neurol 24:21-30. 2004
    b>Myasthenia gravis (MG) is arguably the best understood autoimmune disease, and its study has also led to fundamental appreciation of mechanisms of neuromuscular transmission...
  87. ncbi Comparison between the right side and subxiphoid bilateral approaches in performing video-assisted thoracoscopic extended thymectomy for myasthenia gravis
    C P Hsu
    Division of Thoracic Surgery, Department of Surgery, Taichung Veterans General Hospital, 160, Section 3, Taichung Kang Road, Taichung, Taiwan, Republic of China
    Surg Endosc 18:821-4. 2004
    This study aimed to compare the efficacy of the right thoracoscopic (RtT) approach and the subxiphoid bilateral thoracoscopic (SxBiT) approach in performing thymectomy for myasthenia gravis.
  88. ncbi Utilizing twins concordance rates to infer the predisposition to myasthenia gravis
    Ryan Ramanujam
    Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
    Twin Res Hum Genet 14:129-36. 2011
    b>Myasthenia gravis (MG) is an autoimmune disorder in which patients experience muscular fatigability due to the presence of anti-acetylcholine receptor (AChR) antibodies which inhibit signal transduction across the neuro-muscular junction...
  89. ncbi Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms
    Philipp Strobel
    Institute of Pathology, University Hospital Mannheim, University of Heidelberg, Theodor Kutzer Ufer 1 3, 68135 Mannheim, Germany
    Ann N Y Acad Sci 1132:143-56. 2008
    ..cells and defective production of regulatory CD4(+) T cells inside thymomas contribute to the development of myasthenia gravis (MG) in >90% of MG(+) thymomas. The molecular basis of these abnormalities is unknown...
  90. ncbi Malignant thymoma associated with myasthenia gravis, Graves' disease, and SIADH
    Byung Wan Lee
    Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Seoul, Korea
    Intern Med 47:1009-12. 2008
    ..rare case of a 59-year-old man patient who was discovered to have malignant thymoma associated with myasthenia gravis, Graves' disease, and SIADH. He was admitted for evaluation and treatment of hyponatremia (Na 125 mEq/l)...
  91. ncbi Anesthetic implications of myasthenia gravis
    Mark Abel
    Department of Anesthesiology, Box 1010, Mount Sinai School of Medicine, One East 100th Street, New York, NY 10029 6574, USA
    Mt Sinai J Med 69:31-7. 2002
    b>Myasthenia gravis is a disease of great significance to the anesthesiologist, because it affects the neuromuscular junction...
  92. ncbi Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice
    P I Karachunski
    Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, St Paul, MN 55108, USA
    J Immunol 164:5236-44. 2000
    Immunization with acetylcholine receptor (AChR) causes experimental myasthenia gravis (EMG). Th1 cells facilitate EMG development...
  93. ncbi Preliminary results of VATS thymectomy for pediatric myasthenia gravis
    Ketan Parikh
    Tara Neo Surg Hospital, C 5 Satyam Shopping Centre, MG Road, Ghatkopar E, Mumbai, 400077, India
    Pediatr Surg Int 27:595-8. 2011
    b>Myasthenia gravis (MG) is a debilitating disease which necessitates long-term medical therapy. If left untreated, it can have a high mortality rate...
  94. ncbi Experience with the "da Vinci" robotic system for thymectomy in patients with myasthenia gravis: report of 33 cases
    Federico Rea
    Division of Thoracic Surgery, University of Padua, Padua, Italy
    Ann Thorac Surg 81:455-9. 2006
    Our initial experience in applying robotic-assisted technologies for the treatment of myasthenia gravis (MG) in patients without thymoma is reported.
  95. ncbi The auto-antigen repertoire in myasthenia gravis
    Kathleen Vrolix
    Division of Neuroscience, School of Mental Health and Neuroscience, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands
    Autoimmunity 43:380-400. 2010
    b>Myasthenia Gravis (MG) is an antibody-mediated autoimmune disorder affecting the postsynaptic membrane of the neuromuscular junction (NMJ)...
  96. pmc Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis
    William S Baek
    J Neurol Neurosurg Psychiatry 78:771. 2007
  97. pmc Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin
    J A Aarli
    Department of Neurology, University of Bergen, Norway
    Clin Exp Immunol 82:284-8. 1990
    Patients with myasthenia gravis (MG) and thymoma have in their sera antibodies which react with non-receptor antigens from striated muscle. The purpose of this investigation was to characterize the antigen(s)...
  98. ncbi Immune-mediated rippling muscle disease with myasthenia gravis: a report of seven patients with long-term follow-up in two
    Benedikt Schoser
    Department of Neurology, Friedrich Baur Institute, University of Munich, Ziemssenstr 1a, D 80336 Munich, Germany
    Neuromuscul Disord 19:223-8. 2009
    We report seven patients with immune-mediated rippling muscle disease (iRMD) and AChR-antibody positive myasthenia gravis (MG) without germline caveolin-3 gene mutations...
  99. ncbi Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis
    J M Ponseti
    Myasthenia Gravis Unit, Department of Surgery, Hospital General Universitari Vall d Hebron, Autonomous University of Barcelona, Barcelona, Spain
    Neurology 64:1641-3. 2005
    Seventy-nine patients with cyclosporine- and prednisone-dependent myasthenia gravis (MG) after thymectomy received tacrolimus for a mean of 2.5 +/- 0.8 years. Prednisone was withdrawn in all but two patients...
  100. pmc Evaluation of T cell subsets in myasthenia gravis using anti-T cell monoclonal antibodies
    S Berrih
    Clin Exp Immunol 45:1-8. 1981
    Functional T cell subsets have been evaluated in the peripheral blood of patients with myasthenia gravis using monoclonal anti-T cell antibodies and a suppressor cell assay based on the suppression of the mixed-lymphocyte reaction by ..
  101. pmc Myasthenia gravis presenting as isolated respiratory failure: a case report
    Won Hee Kim
    Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea
    Korean J Intern Med 25:101-4. 2010
    b>Myasthenia gravis (MG) is often complicated by respiratory failure, known as a myasthenic crisis...

Research Grants63

  1. Agrin/alpha 3 Na,K-ATPase signaling at the neuromuscular junction
    Martin A Smith; Fiscal Year: 2012
    ..In many neuromuscular diseases, such as spinal muscular atrophy, myasthenia gravis and congenital myasthenic syndrome, the function of the neuromuscular junction is compromised resulting in ..
  2. The molecular mechanism of Aire: partnering with DNA-PK
    Diane J Mathis; Fiscal Year: 2013
    ..tolerization is thought to play an important role in common autoimmune diseases, notably type-1 diabetes and myasthenia gravis. Successful intervention in the autoimmune disease of Aire-deficient mice with the cancer drug, etoposide, ..
  3. TNIP1 risk haplotypes and immune endophenotypes
    Peter K Gregersen; Fiscal Year: 2013
    ..We have recently reported a remarkably strong association with Myasthenia Gravis (OR, 1.91;p =3...
  4. Phase II Trial of methotrexate in myasthenia gravis FDA IND#:101,306 01/06/2008
    Richard J Barohn; Fiscal Year: 2012
    b>Myasthenia gravis (MG) is characterized by weakness and fatiguability of ocular, bulbar, and extremity musculature...
  5. Structural Mechanism of the Acetylcholine Receptor in Tubular Membrane Crystals
    PETER NIGEL UNWIN; Fiscal Year: 2013
    ..system, and are pharmaceutical targets for numerous human diseases and psychiatric disorders, including myasthenia gravis, neuromuscular degeneration, epilepsy, depression, nicotine addiction, schizophrenia and Alzheimer's ..
  6. Molecular mechanisms of aging in the intrinsic laryngeal muscles
    Colleen McMullen; Fiscal Year: 2009
    ..In addition, the anticipated results will be of relevance to diseases not associated with aging but that affect NMJ structure and function such as myasthenia gravis and the Lambert- Eaton myasthenic syndrome.
  7. Development of Animal Models of Anti-MuSK Myasthenia
    David P Richman; Fiscal Year: 2011
    ..AMM differs from myasthenia gravis (MG) in its severity, the more focal nature of the weakness and the associated muscle wasting...
  8. Augmentation of Parasympathetic Signaling with Pyridostigmine in Heart Failure
    Stuart D Katz; Fiscal Year: 2013
    ..is a short-acting, reversible acetylcholinesterase inhibitor approved by the FDA for the treatment of myasthenia gravis. We now propose a Phase II prospective randomized, double-blind trial to compare 12 weeks of treatment with ..
  9. 12th International Conference on Myasthenia Gravis and Related Disorders
    Gil I Wolfe; Fiscal Year: 2012
    DESCRIPTION: Myasthenia gravis (MG) is a relatively rare, acquired autoimmune syndrome resulting from pathogenic auto- antibodies that cause failure of neuromuscular synaptic transmission...
  10. SIGNALING BY MUSK, A COMPONENT OF THE AGRIN RECEPTOR
    STEVEN BURDEN; Fiscal Year: 2012
    ..Finally, because 20% of patients with myasthenia gravis are sero- negative for auto-antibodies to AChR or MuSK, these individuals presumably carry auto-antibodies ..
  11. 11th International Congress of Neuroimmunology
    Samia J Khoury; Fiscal Year: 2012
    ..for the development of new approaches to treat neuroinflammatory diseases, including multiple sclerosis, myasthenia gravis, CNS gliomas and other disorders...
  12. Role of Daf in Systemic Autoimmunity
    KENNETH MICHAEL POLLARD; Fiscal Year: 2012
    ..Furthermore, Daf1 deficiency was shown to exacerbate lupus, myasthenia gravis and experimental autoimmune encephalomyelitis (EAE) in animal models...
  13. University of Chicago Autoimmunity Center of Excellence
    Marcus R Clark; Fiscal Year: 2013
    ..tolerance in patients with diverse autoimmune diseases including systemic lupus erythematosus (SLE), myasthenia gravis (MG) and inflammatory bowel disease (IBD)...
  14. Pre-Clinical and Clinical Evaluation of Skeletal Muscle Activator, CK-2017357 for
    MALAR PANNIRSELVAM; Fiscal Year: 2012
    ..The objective of this project is to demonstrate a clinical proof-of-concept in myasthenia gravis (MG), a serious autoimmune neuromuscular disorder caused by auto-antibodies to the acetylcholine receptor of ..
  15. Lynx in organization and dynamics of nicotinic acetylcholine receptor complexes
    Julie M Miwa; Fiscal Year: 2013
    ..nAChRs) is linked to neural disorders, including schizophrenia, some epilepsies, nicotine addiction, myasthenia gravis, Alzheimer's disease, and Parkinson's disease...
  16. Long-term rapamycin differentially affects immunity in young and old
    ADRIANA DANIELLE BENAVIDES; Fiscal Year: 2012
    ..To assess whether immune tolerance will be perturbed by rapamycin, a transgenic mouse model of myasthenia gravis will be employed...
  17. Molecular Genetics of HLA and Disease
    Stephen Hauser; Fiscal Year: 2009
    ..The focus is on Multiple Sclerosis, Rheumatoid Arthritis, IgA Deficiency, Common Variable Immunodeficiency, Myasthenia Gravis, Systemic Lupus Erythematosus and Ulcerative Colitis...
  18. Impact of the autoimmunity associated PTPN22 1858T
    Jane Hoyt Buckner; Fiscal Year: 2010
    ..One such genetic variant is the PTPN22 1858T. This variant is associated with T1D, RA, Graves Disease, myasthenia gravis and SLE...
  19. A Phase II Trial of Rituximab In Myasthenia Gravis
    Richard Nowak; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Myasthenia gravis (MG) is an autoimmune disorder of neuromuscular transmission with an estimated annual incidence of about 1-2 per 100,000 and prevalence as high as 20-50 per 100,000...
  20. Molecular Characterization of Extraocular Muscle (EOM)
    Tejvir S Khurana; Fiscal Year: 2010
    ..Enigmatically, EOMs have differential sensitivity to certain diseases. EOMs have prominent involvement in myasthenia gravis, Grave's disease and mitochondrial myopathies;they are spared, however, in Duchenne muscular dystrophy (..
  21. 2nd International Pathogenesis of Rare Neuroimmunologic Disorders
    Douglas Kerr; Fiscal Year: 2006
    ..is an immunemediated[unreadable] injury of the nervous system that include the following: polymyositis, myasthenia gravis (MG),[unreadable] inflammatory polyneuropathies, transverse myelitis, HTLV-1 associated myelopathy, stiff ..
  22. AIRE, a zinc-finger protein that controls autoimmunity
    Diane J Mathis; Fiscal Year: 2013
    ..have also been implicated in certain of the more common autoimmune disorders, notably type-1 diabetes and myasthenia gravis. The project proposed herein will focus on the novel, very surprising, finding that Aire's impact on ..
  23. Impact of the autoimmunity associated PTPN22 1858T
    Jane Hoyt Buckner; Fiscal Year: 2013
    ..One such genetic variant is the PTPN22 1858T. This variant is associated with T1D, RA, Graves Disease, myasthenia gravis and SLE...
  24. LRP4 signaling in neuromuscular junction formation
    Lin Mei; Fiscal Year: 2013
    ..Recent evidence from various laboratories including ours indicates that patients with myasthenia gravis (MG) develop antibodies against MuSK and LRP4...
  25. Signaling by MuSK, a component of the Agrin receptor.
    STEVEN BURDEN; Fiscal Year: 2013
    ..As such, these studies are likely to shed new light into neuromuscular diseases, including amyotrophic lateral sclerosis, congenital myasthenia, myasthenia gravis and age-related muscle wasting, sacropenia.
  26. ACETYLCHOLINESTERASE-CATALYZED HYDROLYSIS
    Daniel Quinn; Fiscal Year: 1991
    ..Other AChE inhibitors are useful in the treatment of myasthenia gravis, glaucoma, and perhaps Alzheimer's disease...
  27. MICROSENSOR FOR INTRAMUSCULAR PRESSURE MEASUREMENT
    Kenton R Kaufman; Fiscal Year: 2013
    ..g. motor neuron disease, peripheral neuropathy), disorders of neuromuscular transmission (e.g. myasthenia gravis, Lambert-Eaton syndrome) and myopathies (e.g. muscular dystrophies, polymyositis, metabolic myopathies).
  28. Thymectomy in Non-Thymomatous MG Patients on Prednisone
    Gary Cutter; Fiscal Year: 2013
    ..is a multi-center, single-blind, randomized study comparing thymectomy to no thymectomy in non-thymomatous myasthenia gravis (MG) patients receiving prednisone. This NINDS-sponsored project was initiated in September, 2005...
  29. Wnt Signaling in Synaptic Prepattern formation and Motor Axon Guidance
    Laura R Gordon; Fiscal Year: 2011
    ..human diseases in that MuSK is a target of antibody- mediated autoimmune attack in the neuromuscular disease myasthenia gravis. Furthermore, mutations in components of the MuSK pathway are responsible for human congenital myasthenic ..
  30. Utilization of a motility mutant to elucidate myotome formation in zebrafish
    Ethan Carver; Fiscal Year: 2009
    ..of the neuromuscular system can lead to congenital diseases and disorders such as muscular dystrophy, myasthenia gravis, myopathies, myoglobinuria, Limb-Girdle Syndromes, ataxias, paralysis and spastic paraparesis (Amack and ..
  31. Pathogenesis of Rare Neuroimmunologic Disorders
    Douglas Kerr; Fiscal Year: 2004
    ..There are a variety of rare neuroimmunologic disorders: polymyositis, myasthenia gravis, CIDP, transverse myelitis, TSP/HAM, stiff person syndrome, neuromyelitis optica, optic neuritis, ADEM, ..
  32. Stimulating Young Neuroscientists And Physiologists in Science Education - Phase
    JARED JACKSON; Fiscal Year: 2013
    ..potential and actions potentials (Epilepsy), nerve-to-nerve (Parkinson's disease) and neuromuscular (Myasthenia Gravis) synaptic transmission...
  33. Transmitter Repletion: Key to Phrenic-Diaphragm Function
    Erik van Lunteren; Fiscal Year: 2005
    ..This occurs not only in overtly diseased neuromuscular junctions (eg. myasthenia gravis, botulism), but also in normal junctions subjected to high intensity activation during mechanical loading by ..
  34. CSF Indicators for Diagnosis and Disease Progression of ALS
    Carol Milligan; Fiscal Year: 2009
    ..Specific biologic markers for diseases such as lupus, paraneoplastic syndromes, and myasthenia gravis directly reflect the cause of these diseases and are the preferred diagnostic methods...
  35. IMMUNOBIOLOGY OF AUTOIMMUNITY
    Vanda Lennon; Fiscal Year: 1990
    ..on a new concept of the role of the thymus in at least one form of autoimmunity, the neuromuscular disease myasthenia gravis (MG)...
  36. 11th International Myasthenia Gravis Meeting
    RICHARD BAROHN; Fiscal Year: 2007
    ..The New York Academy of Sciences is planning a major three day conference entitled "The 11th International Myasthenia Gravis Foundation of America Meeting" to be held May 14-16, 2007 at the Chicago Renaissance Hotel, Chicago, IL...
  37. Temporal and Spatial patterns of structural proteins in extraocular muscles
    CAROLE MONCMAN; Fiscal Year: 2009
    ..dystrophies and on the other hand are specifically targeted in oculopharyngeal muscular dystrophy and myasthenia gravis. The hypothesis driving this proposal is that the unique nature of the myogenesis, myofibrillogenesis and ..
  38. SUPPRESSION OF CNS AUTOIMMUNE DISEASE BY TH2 CELLS
    Stephen Stohlman; Fiscal Year: 2005
    ..with the increased prevalence of a number of human autoimmune diseases including multiple sclerosis, myasthenia gravis, rheumatoid arthritis and SLE...
  39. MULTITASK ASSESSMENT OF MOTOR UNIT FATIGUE
    ANDREW FUGLEVAND; Fiscal Year: 1999
    ..workplace, it is a debilitating factor in a number of neuromuscular diseases including muscular dystrophy, myasthenia gravis, and multiple sclerosis, it has been implicated as a contributor to neonatal respiratory failure, and it ..
  40. DEVELOPMENT OF NEURONAL NICOTINIC RECEPTOR PROBES
    Gregory Grant; Fiscal Year: 1992
    ..neuronal nicotinic receptor may exist which would be analogous to the attack on the muscle receptor seen in Myasthenia Gravis. Our understanding of these processes should be facilitated as more information is gathered concerning the ..
  41. Utility of the P300 Brain-Computer Interface for Patients in Acute Care Environme
    Leigh Hochberg; Fiscal Year: 2009
    ..g., myasthenia gravis, Guillain-Barre Syndrome), or multi-trauma can leave patients awake and hospitalized, yet unable to ..
  42. CHARACTERIZATION OF DISEASE-CAUSING ANTIBODIES IN EAMG
    Keith Krolick; Fiscal Year: 1993
    The immunopathology of Experimental Autoimmune Myasthenia Gravis (EAMG) in rats involves a neuromuscular impairment caused by a T cell dependent antibody response against the post-junctional acetylcholine receptor (AChR)...
  43. NOVEL THERAPY OF MYASTHENIA BY REDUCING ACHR ENDOCYTOSIS
    RALPH KUNCL; Fiscal Year: 1990
    The goal of this study is to exploit detailed knowledge of the pathogenesis of myasthenia gravis (MG) to design rational and effective treatments that avoid some of the problems of existing immunosuppressive drugs...
  44. NITRIC OXIDE IN NORMAL AND DISEASED OCULAR MUSCLE
    HENRY KAMINSKI; Fiscal Year: 2000
    ..Further, modulation of neuromuscular transmission by nitric oxide drugs may be useful in treatment of myasthenia gravis, a disorder which preferentially affects extraocular muscle...
  45. REGULATION OF ACETYLCHOLINE RECEPTORS ON MUSCLE
    Paul Brehm; Fiscal Year: 2004
    ..Two lines exhibit myasthenia gravis-like symptoms in the form of use-dependent fatigue, and the symptoms can be partially rescued by inhibitors ..
  46. VIIITH INTERNATIONAL CONFERENCE ON MYASTHENIA GRAVIS
    AUDREY PENN; Fiscal Year: 1992
    We are proposing to hold the VIIIth International Conference on Myasthenia Gravis in Washington, D>C> in April, 1992, under the auspices of the New York Academy of Sciences...
  47. CHARACTERIZATION OF THE HUMAN HAIR CELL RECEPTOR ALPHA-9
    LAWERENCE LUSTIG; Fiscal Year: 2004
    ..mutations and disorders of nicotinic receptor function have been implicated in such diverse diseases as myasthenia gravis, nocturnal frontal lobe epilepsy and schizophrenia...
  48. Thymectomy in Non-Thymomatous MG Patients on Prednisone
    Camilla Buckley; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Myasthenia gravis (MG) is an autoimmune disease involving the thymus in which 85% of patients have antibodies to muscle acetylcholine receptors (AchR-Ab) that interfere with neuromuscular ..
  49. IMMUNOTHERAPY OF MYASTHENIA GRAVIS
    J Blalock; Fiscal Year: 2001
    DESCRIPTION (Adapted from Investigator's abstract): Myasthenia gravis (MG) and experimental autoimmune myasthenia gravis (EAMG) are caused, in part, by the production of T-cell-dependent, autoantibodies against the main immunogenic ..
  50. ECM MOLECULES IN NEUROMUSCULAR JUNCTION DEVELOPMENT
    EARL GODFREY; Fiscal Year: 1991
    ..of factors that influence synapse formation may aid in understanding neuromuscular disorders such as myasthenia gravis. The specific hypothesis to be tested is that molecules in the synaptic basal lamina direct the ..
  51. ACETYLCHOLINE RECEPTOR TURNOVER IN MYASTHENIA GRAVIS
    Stanley Appel; Fiscal Year: 1980
    b>Myasthenia gravis is a remitting and relaxing neuromuscular disease of man characterized by muscle fatiguability which increases with exertion and improves with rest...
  52. The role of regulatory T cells in maintaining B cell tolerance
    Daniel Campbell; Fiscal Year: 2007
    ..such as systemic lupus erythematosus, idiopathic thrombocytopenia purpura, autoimmune hemolytic anemia, and myasthenia gravis. Moreover, autoantibodies are also frequently observed in type 1 diabetes, rheumatoid arthritis, and ..
  53. EXPERIMENTAL AUTOIMMUNE AUTONOMIC NEUROPATHY
    Steven Vernino; Fiscal Year: 2005
    ..from the Applicant's Abstract): The discovery of acetylcholine receptor (AChR) antibodies in patients with myasthenia gravis (MG) led to recognition of other IgG-mediated neurologic diseases and had practical implications for ..
  54. SYMPATHETIC NERVOUS SYSTEM AND IMMUNE RESPONSES
    Ewa Chelmicka Schorr; Fiscal Year: 1992
    ..autoimmune diseases: Experimental Allergic Encephalomyelitis (EAE) and experimental autoimmune myasthenia gravis (EAMG). We will now study the influence of the SNS on macrophage function...
  55. Targeted Therapies for Myasthenia Gravis
    HENRY KAMINSKI; Fiscal Year: 2007
    DESCRIPTION (provided by applicant): Myasthenia gravis (MG) is an antibody-mediated autoimmune disorder, which compromises neuromuscular junction function...
  56. DETERMINANTS OF DISEASE IN EXPERIMENTAL MYASTHENIA GRAVI
    Keith Krolick; Fiscal Year: 2000
    DESCRIPTION: (Applicant's abstract): Experimental autoimmune myasthenia gravis (EAmyasthenia gravis) in Lewis rats involves a neuromuscular impairment caused by a T cell dependent antibody response against the post-junctional ..
  57. SPECIFIC IMMUNOTHERAPY OF MYASTHENIA--SAFE STRATEGIES
    DANIEL DRACHMAN; Fiscal Year: 2000
    DESCRIPTION: The pathogenesis of myasthenia gravis (MG) involves an antibody-mediated autoimmune response directed against acetylcholine receptors (AChR)...
  58. FOUR SELECTED PROBLEMS IN NEUROMUSCULAR TRANSMISSION
    WILLIAM NASTUK; Fiscal Year: 1980
    Project I. Experimental models of myasthenia gravis. Frogs are immunized with native and chemically modified acethylcholine receptor. Pre and postsynaptic changes in ultra-structure of the neuromuscular junction are determined...
  59. ANTIGEN SPECIFIC IMMUNE DEVICE FOR MYASTHENIA GRAVIS
    Sohel Talib; Fiscal Year: 1990
    DESCRIPTION: (Applicant's Abstract) "Although Myasthenia Gravis (MG) is the best characterized human autoimmune disease, no cure is available...
  60. ANTIFACTOR VIII CD4+ CELLS IN HEMOPHILIA
    Bianca Conti Fine; Fiscal Year: 2001
    ..were very effective in preventing and down regulating another Ab-mediated mouse syndrome, experimental myasthenia gravis. Also, we will investigate the epitope repertoire of human anti-fVIII CD4+ cells...
  61. TRAINING GRANT IN NEUROMUSCULAR DISEASES AND BIOLOGY
    DANIEL DRACHMAN; Fiscal Year: 2003
    ..areas include: amyotrophic lateral sclerosis; spinal muscular atrophy; peripheral neuropathies; myasthenia gravis; muscular dystrophies; and autoimmune myopathies...
  62. T CELL RECEPTOR EXPRESSION IN MYASTHENIA GRAVIS
    Anthony Infante; Fiscal Year: 1999
    DESCRIPTION (Adapted from Investigator's abstract): Myasthenia gravis (MG) is a disease manifested by muscle weakness and exaggerated fatigue due to impaired signal transduction at the neuromuscular junction...
  63. REGULATION OF MUSCLE ACETYLCHOLINE RECEPTOR
    Jakob Schmidt; Fiscal Year: 2001
    ..for a better understanding of neurological and neuromuscular disorders such as Alzheimer's disease or myasthenia gravis. The denervation-induced increase in acetylcholine receptor synthesis rate will be investigated in chick ..